June 02, 2021
Government Operations Results for April 2021
For the period of April 2021, the GOJ reported Total Revenues & Grants of $75.73 billion, $3.41 billion more than the Government’s projection. This represented an increase of approximately 105.1% relative to the $36.92 billion recorded for the corresponding period in 2020. ‘Grants’ amounted to $93.5 million during the review period and underperformed the budget by $222.8 million. Conversely, ‘Non-Tax Revenue’ amounted to $34.52 billion, $190.8 million more than budgeted. ‘Tax Revenue’ of $41.12 billion was reported, $3.45 billion more than budgeted. Notably, there were no budgeted amounts for ‘Bauxite Levy’ and ‘Capital Revenue’, and no provisions were made for the period.
Expenditures
Total Expenditure for the period April 2021 amounted to $63.70 billion, $3.42 billion less than the budgeted amount of $67.12 billion. Recurrent expenditure which totalled $56 billion, accounted for 87.87% of overall expenditures. Of the recurrent expenditure categories for the review period, the categories below the budgeted amount were ‘Programmes’, ‘Compensation of Employees’, ‘Wages & Salaries’ and ‘Employee Contribution’. ‘Programmes’ totalled $22.61 billion, 10.7% less than budgeted. ‘Compensation of Employees’ amounted to $21.46 billion and was $697.6 million or 3.1% less than budgeted. ‘Wages & Salaries’ totalled $18.35 billion, while ‘Employee Contribution’ ended $3.10 billion, both 3.6% and 0.2% below the budgeted amount. Relative to projections, ‘Interest’ totalled $11.90 billion, $322.4 million more than budgeted.
The ‘Fiscal Surplus’ was $12.03 billion, relative to a ‘Projected Surplus’ of $5.20 billion. Additionally, the ‘Primary Surplus Balance’ for the period amounted to $23.94 billion, relative to the budgeted primary surplus of $16.76 billion.
Disclaimer:
Analyst Certification –The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation (s) or view (s) expressed by that research analyst in this research report.
Company Disclosure –The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.